Acceptability and tolerability of longacting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV IMPAACT 2017MOCHA a second analysis of a phase 12 multicentre openlabel noncomparative dos

Simple item page
dc.article.end-page232en
dc.article.start-page222en
dc.citation.doi10.1016/S2352-3018(23)00301-6.en
dc.contributor.authorE Lowenthalen
dc.contributor.authorj Chapmanen
dc.contributor.authorR Ohrenschallen
dc.contributor.authork calabreseen
dc.contributor.authorFaeezah Patelen
dc.contributor.authorE et alen
dc.date.accessioned2025-01-21T13:32:27Z
dc.date.available2025-01-21T13:32:27Z
dc.departmentWITS REPRODUCTIVE HEALTH AND HIV INSTITUTEen
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationWOSen
dc.identifier.issn2352-3018en
dc.identifier.urihttps://hdl.handle.net/10539/43570
dc.journal.titleAcceptability and tolerability of longacting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV IMPAACT 2017MOCHA a second analysis of a phase 12 multicentre openlabel noncomparative dosen
dc.journal.volume11en
dc.publisherELSEVIER SCIENCE INCen
dc.titleAcceptability and tolerability of longacting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV IMPAACT 2017MOCHA a second analysis of a phase 12 multicentre openlabel noncomparative dosen
dc.typeJournal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal Article.pdf
Size:
279.04 KB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client
Download

Collections

Academic Wits Research Outputs (All submissions)